

Recent advances in the treatment of acute myeloid leukemia

Omar Abdel-Wahab and Ross L Levine*

Address: Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

* Corresponding author: Ross L Levine (leviner@mskcc.org)

F1000 Medicine Reports 2010, 2:55 (doi:10.3410/M2-55)

The electronic version of this article is the complete one and can be found at: <http://f1000.com/reports/medicine/content/2/55>

Abstract

Acute myeloid leukemia (AML) is a disorder with significant molecular and clinical heterogeneity. Although there have been clear advances in the identification of somatic genetic and epigenetic alterations present in the malignant cells of patients with AML, translating this knowledge into an integrated view with an impact on the clinical treatment of AML has been slower to evolve. Recent clinical advances in the treatment of AML include studies demonstrating the benefit of dose-intense daunorubicin therapy in induction chemotherapy for patients of any age. We also review use of the DNA methyltransferase inhibitor azacitidine for treatment of AML in elderly patients as well as a study of global patterns of DNA methylation in patients with AML. Lastly, we review a recent assessment of the role of allogeneic hematopoietic stem cell transplantation in AML in first complete remission.

Introduction and context

Acute myeloid leukemia (AML) is the more common acute leukemia in adults. Genetic and functional studies have demonstrated that AML develops as a result of acquisition of genetic and epigenetic alterations that result in abnormal differentiation and unlimited self-renewal. Although patients with AML, with the exception of acute promyelocytic leukemia, are treated with similar therapies, it has long been recognized that there is significant biological, clinical, and genetic heterogeneity in AML. Recent genetic studies have continued to elucidate molecular alterations in AML with clinical and prognostic significance, and there is an ever-increasing list of somatic genetic abnormalities described in AML. In addition to mutations in *MLL*, *Flt3*, *NPM1*, *CEBPa*, *K/N-Ras*, *KIT*, and *WT1*, mutations in the putative epigenetic modifiers *TET2* [1-4] and *ASXL1* [2,5] as well as in the metabolic enzymes *IDH1* and *IDH2* [6,7] have been described in AML in the past year.

Although increasing knowledge of the genetic abnormalities present in AML has continued to improve our

understanding of the biology of this disorder, an integrated view of the genetic and epigenetic abnormalities found in AML is greatly needed. Even more challenging will be translating such a comprehensive characterization into a clinically useful decision algorithm.

In this review, we summarize the findings from four recent clinical studies of treatment in AML. The first two studies focus on optimizing induction chemotherapy regimens in AML using anthracycline dose-intensification. The third study evaluates the role of the DNA methyltransferase inhibitor azacytidine in the treatment of elderly patients with AML and a low blast count. The final study is a discussion of a recent meta-analysis regarding the use of allogeneic hematopoietic stem cell transplantation (HSCT) in first remission of AML.

Recent advances

Optimizing induction chemotherapy in AML with anthracycline dose-intensification

The current standard of care for induction chemotherapy of AML is 3 days of an anthracycline and 7 days of

cytarabine (100-200 mg/m² continuous intravenous) [8]. While attempts to increase response rate with the addition of agents such as thioguanine [9], etoposide [10], fludarabine [11], and topotecan [11] have failed, two studies published in the fall of 2009 demonstrated that intensification of the dose of daunorubicin improves outcome in *de novo* AML [12,13].

The first study by the Eastern Cooperative Oncology Group randomized previously untreated AML patients aged 17-60 years to standard dose (45 mg/m²) or high-dose (90mg/m²) daunorubicin in combination with 7 days of cytarabine (100 mg/m² continuous infusion) [12]. Patients in complete remission (CR) were then offered allogeneic HSCT or high-dose cytarabine, with or without gemtuzumab ozogamicin, followed by allogeneic HSCT. Treatment with high-dose daunorubicin resulted in improved CR rate (70.6% versus 57.3%, $P < 0.001$) and longer overall survival (OS; median, 23.7 versus 15.7 months).

As the results of this study were published, Löwenberg *et al.* [13] simultaneously reported the use of a similar daunorubicin dose-intensification induction regimen in elderly AML patients. In this study, newly diagnosed AML patients aged 60 years or older (median age 67) were randomly assigned to receive cytarabine (200 mg/m² continuous intravenous infusion) plus daunorubicin for 3 days at the conventional dose of 45 mg/m² or at the escalated dose of 90 mg/m². This treatment was then followed by a second cycle of cytarabine at a dose of 1000 mg/m² every 12 hours for 6 days. The elevated dose of daunorubicin led to an increased CR rate (64% versus 54%, $P = 0.002$) but did not affect OS in the study in general. However, there was a significant improvement in OS in patients aged 60-65 years who received the higher-dose of daunorubicin compared with the conventional dose.

Importantly, in both studies, treatment with high-dose daunorubicin did not result in significant differences in hematologic toxicity or adverse events. Moreover, treatment with high-dose daunorubicin did not prolong time to receive consolidation therapy. These studies suggest that there is a dose-response relationship between anthracycline therapy and AML, and that anthracycline dose-intensification results in improved responses without marked increases in attendant toxicity. Whether dose-intensified daunorubicin is associated with improved long-term survival remains to be seen given the short duration of follow-up for these studies, and more importantly, whether specific

molecularly defined subtypes of AML specifically benefit from dose-intensified induction regimens.

Use of azacytidine as treatment in AML

Given that most patients with AML are aged 60 years or older and that treatment with intensive chemotherapy (such as the dose-intense daunorubicin plus cytarabine induction described above) is limited to 30-60% of elderly AML patients [14], there has been great interest in developing alternative therapeutic strategies for elderly AML patients. However, clinical trials with low-dose cytarabine [15], the farnesyl transferase inhibitor tipifarnib [16], and gemtuzumab ozogamicin [17] have demonstrated little or no improvement in overall survival in elderly patients with AML. Importantly, a recent phase III randomized trial of the DNA methyltransferase inhibitor azacytidine demonstrated an improvement in survival as a single agent in older AML patients with 20-30% bone marrow blasts compared with 'conventional care regimens' [18]. In this study, conventional care regimens were defined as best supportive care, low-dose cytarabine, or intensive chemotherapy. Most patients (86%) were considered unfit for intensive chemotherapy and azacytidine resulted in an overall survival of 24.5 months compared with 16.0 months for patients receiving conventional care regimens ($P < 0.001$). Moreover, azacytidine was associated with fewer days in hospital and higher two-year overall survival rates.

With further clinical study of epigenetic targeted therapies in AML, it will be important to correlate response to epigenetic therapies with genome-wide methylation data before and after treatment. The largest study of the genome-wide methylation status of AML genomes was recently published by Figueroa *et al.* [19]. In this study, genome-wide promoter DNA methylation profiling was performed using the HELP assay (HpaII tiny fragment enrichment by ligation-mediated PCR). In the first part of the study the authors found that the known cytogenetic subsets of AML (e.g., t(15;17), inv(16), t(11q23)) were associated with distinct global DNA methylation patterns. More interestingly, the authors then integrated DNA methylation array data with gene-expression profiling and identified unique subsets of AML. These specific subsets of AML did not align with kinase abnormalities described in AML (mutations in *Flt3*, *N/K-Ras*, *CBL*, *KIT*, *JAK2*), suggesting that methylation and gene-expression changes in AML may be influenced by alterations other than single activating kinase mutations. As the molecular characterization of the epigenetic machinery and landscape of AML improves, it will be interesting to correlate data from

genome-wide methylation patterns of AML with mutations in epigenetic modifiers and with response to epigenetic targeted therapy.

Current state of allogeneic HSCT for AML in first remission

The goal of therapy in the treatment of younger patients with AML is to achieve a cure. While $\geq 70\%$ of patients with AML aged < 60 years will achieve first CR (CR1), a substantial number of patients relapse during or after consolidation therapy [20]. Thus, treatment with allogeneic HSCT in young patients with AML in CR1 has been frequently studied, but until recently the use of allogeneic HSCT was not well-defined for all risk groups of AML. Less than 1 year ago, Koreth *et al.* [21] performed a meta-analysis of all published data on the use of allogeneic HSCT versus non-allogeneic HSCT options (autologous HSCT, consolidation chemotherapy, or both) for patients with AML aged < 60 years in CR1. They used an intention-to-treat analysis based on donor availability to capture information from all patients with AML evaluated for up-front allogeneic HSCT with a donor search as part of a prospective trial. They found that allogeneic HSCT significantly improved relapse-free survival and OS for intermediate- and poor-risk AML (based on cytogenetic risk) but not in good-risk AML in CR1. Five-year OS was estimated at 45% and 20% for intermediate- and poor-risk AML, respectively, with non-allogeneic HSCT options. This is compared with OS rates of 52% and 31% for patients with intermediate- and poor-risk AML, respectively, who underwent allogeneic HSCT.

Previous studies have shown that mutational status is an important predictor of outcome and treatment response in AML, including response to allogeneic HSCT. The landmark study by Schlenk *et al.* [22] demonstrated the importance of correlating mutational status of normal karyotype AML patients with likelihood of attaining complete remission after chemotherapy and chance of benefiting from an allogeneic HSCT. In this study, the mutational status of *NPM1*, *Flt3*, *CEBPa*, *MLL*, and *N-Ras* were assessed in 872 adults aged < 60 years with cytogenetically normal AML. In addition to revealing the mutational frequency of each of these genes in normal karyotype AML, the study more importantly demonstrated that the factors associated with CR in normal karyotype AML include the genotype of mutant *NPM1* without *FLT3* internal tandem duplication (ITD), the mutant *CEBPA* genotype, and younger age. Moreover, because 150 individuals in this study underwent HSCT from an HLA-matched related donor, the authors were able to identify that the benefit of the transplant was limited to the subgroup of patients with *FLT3* ITD or the genotype consisting of wild-type *NPM1* and *CEBPA* without *FLT3* ITD.

Implications for clinical practice

The recent clinical studies reviewed here demonstrate the benefit of high-dose daunorubicin in induction therapy of AML for patients of any age eligible to receive intensive chemotherapy [12,13]. Following successful achievement of complete remission, recent detailed meta-analyses suggest that allogeneic HSCT is beneficial for any patient in cytogenetically defined intermediate- or poor-risk categories [21]. For elderly AML patients with $< 30\%$ bone marrow blasts who are not eligible to receive intensive chemotherapy, treatment with azacitidine appears to improve OS compared with alternative treatments [18]. Given that many molecular alterations in AML have been demonstrated to influence response to clinical therapies [8,12], further efforts to integrate genome-wide molecular alterations with treatment response and outcome are needed and will inform future analyses of the cohorts described in these clinical trials. Characterization of primary AML samples by the use of high-throughput genetic, epigenetic, and RNA/microRNA expression techniques continues to improve, and it will be important to incorporate molecular analyses into existing and future clinical trials to delineate genetic and epigenetic predictors of response and outcome to specific therapies. With the identification of new mutated genes in AML since the publication of the study by Schlenk *et al.* [22] as well as the ability to profile the epigenetic state of AML samples, it will be intriguing to repeat such correlative efforts. In particular, it will be especially useful to use this biological information to ascertain the benefit of response to allogeneic HSCT for those under the age of 60 and the likelihood of achieving CR for the elderly with AML.

Abbreviations

AML, acute myeloid leukemia; CR, complete remission; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; ITD, internal tandem duplication; OS, overall survival; PCR, polymerase chain reaction.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

RLL is a recipient of an Early Career Award from the Howard Hughes Medical Institute, a Clinical Scientist Development Award from the Doris Duke Charitable Foundation, and is the Geoffrey Beene Junior Chair at Memorial Sloan-Kettering Cancer Center. RLL is also supported by the National Institutes of Health (grant HL082677).

References

- Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinger S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL: **Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.** *Blood* 2009, **114**:144-7.
 - Abdel-Wahab O, Manshoury T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S: **Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.** *Cancer Res* 2010, **70**:447-52.
- F1000 Factor 3.0 Recommended
Evaluated by Alessandro Vannucchi 08 Apr 2010
- Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenbergh P, de Witte T, van der Reijden BA, Jansen JH: **Acquired mutations in TET2 are common in myelodysplastic syndromes.** *Nat Genet* 2009, **41**:838-42.
- F1000 Factor 3.0 Recommended
Evaluated by Effie Petersdorf 29 Jul 2009
- Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguier F, Fontenay M, Vainchenker W, Bernard OA: **Mutation in TET2 in myeloid cancers.** *N Engl J Med* 2009, **360**:2289-301.
- F1000 Factor 3.0 Recommended
Evaluated by Richard Larson 25 Aug 2009
- Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adélaïde J, Olschwang S, Xerri L, Vey N, Chaffain M, Birnbaum D, Mozziconacci MJ: **Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.** *Leukemia* 2010, **24**:469-73.
 - Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, et al.: **Recurring mutations found by sequencing an acute myeloid leukemia genome.** *N Engl J Med* 2009, **361**:1058-66.
- F1000 Factor 6.0 Must Read
Evaluated by Jean Clairambault 25 Aug 2009
- Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Collier HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB: **The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.** *Cancer Cell* 2010, **17**:225-34.
 - Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD; European LeukemiaNet: **Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.** *Blood* 2010, **115**:453-74.
 - Ruutu T, Koivunen E, Nousiainen T, Pelliniemi TT, Almqvist A, Anttila P, Jantunen E, Koistinen P, Koponen A, Mikkola M, Oksanen K, Pulli T, Remes K, Sarkkinen R, Silvennoinen R, Timonen T, Vanhatalo S, Elonen E; Finnish Leukaemia Group: **Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.** *Eur J Haematol* 2004, **72**:38-44.
 - Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A, Herrmann R, Szer J, Wolf MM, Young G: **Etoposide in acute nonlymphocytic leukemia.** *Australian Leukemia Study Group.* *Blood* 1990, **75**:27-32.
 - Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M: **Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.** *Blood* 2001, **98**:3575-83.
 - Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS: **Anthracycline dose intensification in acute myeloid leukemia.** *N Engl J Med* 2009, **361**:1249-59.
 - Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group: **High-dose daunorubicin in older patients with acute myeloid leukemia.** *N Engl J Med* 2009, **361**:1235-48.
- F1000 Factor 4.8 Must Read
Evaluated by Heidi Klepin 13 Oct 2009, Arati Rao 14 Oct 2009
- Deschler B, de Witte T, Mertelsmann R, Lubbert M: **Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.** *Haematologica* 2006, **91**:1513-22.
 - Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K: **A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.** *Cancer* 2007, **109**:1114-24.
 - Karp JE, Lancet JE: **Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.** *Biologics* 2008, **2**:491-500.
 - Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group: **Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.** *J Clin Oncol* 2001, **19**:3244-54.
 - Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR: **Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.** *J Clin Oncol* 2010, **28**:562-9.
- F1000 Factor 3.0 Recommended
Evaluated by Arati Rao 16 Mar 2010
- Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Grealley JM, Valk PJ, Löwenberg B, Delwel R, Melnick A: **DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.** *Cancer Cell* 2010, **17**:13-27.
- F1000 Factor 6.0 Must Read
Evaluated by Lee Grimes 21 Jan 2010
- Lowenberg B, Downing JR, Burnett A: **Acute myeloid leukemia.** *N Engl J Med* 1999, **341**:1051-62.

21. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C: **Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.** *JAMA* 2009, **301**:2349-61.
22. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group: **Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.** *N Engl J Med* 2008, **358**:1909-18.

F1000 Factor 3.0 *Recommended*
Evaluated by Andreas Engert 16 Oct 2009

F1000 Factor 6.4 *Must Read*
Evaluated by Effie Petersdorf 20 Aug 2008, Richard Larson 26 Sep 2008